{"name":"Calliditas Therapeutics","slug":"calliditas","ticker":"CALT","exchange":"NASDAQ","domain":"calliditas.com","description":"Calliditas Therapeutics is a biopharmaceutical company focused on developing innovative treatments for nephrology and rare diseases. The company's lead product, Nefecon, is an oral formulation of budesonide for the treatment of IgA nephropathy. Calliditas has a strong pipeline and a growing presence in the nephrology and rare disease markets.","hq":"Stockholm, Sweden","founded":2015,"employees":"~100","ceo":"Renee Aguiar-Lucander","sector":"Nephrology / Rare Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.3B","metrics":{"revenue":320000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Nefecon patent cliff ($0.0B at risk)","drug":"Nefecon","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"TARPEYO®","genericName":"TARPEYO®","slug":"tarpeyo","indication":"Other","status":"marketed"},{"name":"NEFECON","genericName":"NEFECON","slug":"nefecon","indication":"IgA nephropathy with risk of progression to end-stage renal disease","status":"phase_3"},{"name":"Xepol","genericName":"Xepol","slug":"xepol","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"TARPEYO®","genericName":"TARPEYO®","slug":"tarpeyo","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NEFECON","genericName":"NEFECON","slug":"nefecon","phase":"phase_3","mechanism":"Nefecon is a targeted immunosuppressant that delivers budesonide directly to the kidney to reduce inflammation in IgA nephropathy.","indications":["IgA nephropathy with risk of progression to end-stage renal disease"],"catalyst":""},{"name":"Xepol","genericName":"Xepol","slug":"xepol","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2022-06-15","type":"regulatory","headline":"FDA Approves Nefecon for IgA Nephropathy","summary":"The US FDA approved Nefecon, an oral formulation of budesonide, for the treatment of IgA nephropathy.","drugName":"Nefecon","sentiment":"positive"},{"date":"2022-03-14","type":"earnings","headline":"Calliditas Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"Calliditas reported its financial results for the fourth quarter and full year 2021, highlighting progress in its pipeline and commercialization efforts.","drugName":"","sentiment":"neutral"},{"date":"2021-09-14","type":"deal","headline":"Calliditas Enters into Agreement with AstraZeneca for Nefecon","summary":"Calliditas entered into an agreement with AstraZeneca for the commercialization of Nefecon in the US, Europe, and other territories.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOOGhXTUZPQjZMYnp5cmZiSk1Da2dScEh6dHVQdmpHN0RKcmp6MFZ1dXgtT3BuR2hTR1owclhTV1RhVWc4Zm9Md1A3cmZWLXBPZFhLY1ZWc01mUGRPRDRELWh6V1lGaUxXY1NjRnVzU2RDQ1NJa1RlbE1FMWhMV2hXZFc2Vms4bHlVbjFfNlBEY2RzS1dqV3dFV3l4OXZ4XzF5V1l5Uk9QZEo?oc=5","date":"2026-04-01","type":"pipeline","source":"The Pharma Letter","summary":"ICER ‘s final evidence report on therapies for IgA nephropathy - The Pharma Letter","headline":"ICER ‘s final evidence report on therapies for IgA nephropathy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1ReEcxbU1IdXB1aUtIQ2l4dEh0YTJ6V3hDZ0pYbS1ZQ2FTUWJKNF9PaEZFTWc2SFNneFBvcHlBcG5EZFM4bm9MVzUxT0g2b1FZeGZV?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"CALT Stock Price, News & Analysis - Stock Titan","headline":"CALT Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOV3drWW9uTEJXU3hWamgyRlljYkZGQmRiaDJVYVZqano5Z2pnOGRDM3FEcHpWU3lldXVyUTZVTWZlS05zRldxMUM3c1V0WUp0cEVkZEhIaE9ER0plVGdfemF1d3ZuV0d4Wk5LNjBPQXFKUDE4ZUpYS0F4bGl1dWVidUxWT0Y1VE9zX2ZNMExma1lGS1lMRkVEQ1EwLWE0WWZSY1E?oc=5","date":"2024-05-28","type":"pipeline","source":"Seeking Alpha","summary":"Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics (NASDAQ:CALT) - Seeking Alpha","headline":"Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics (NASDAQ:CALT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxORU1LWmZmMURqUDNZSnFZLTdHNFZGTTBwQ0hHeHlDLTRLMTA3TTVMWUpQU2k0QXNrTmFybTRCc1lQUHprUFhGZmxyMHBnTXpBaW5PNE9PVnA0a3lLYnVVN2NiMXpoNDRJZmZ1MExEWVdvYUdIdXdhZVJ4eUV1dkNKSFdxc25OX29DdlhoUldpTS1ZendpRzZ2am1iMnNLdUVpN1pzeW1sWEU3bkVJVnVWdVAzLUdFc3NObEliM2FUMA?oc=5","date":"2024-04-11","type":"pipeline","source":"Seeking Alpha","summary":"What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences (VRTX) - Seeking Alpha","headline":"What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences (VRTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxQemtPZGkzMVVfeXJxQjFuczRFQXZDX1ZsM0NaM2VadV9XdV9vS1hMeVJ4VjdfRFJFRFZvSmt5S3lGZzVHY1UxRnUxVkl3WEg0UWZjamNCTVNGdFA2dUZUaEEwdWxlajd4UHNUZnVvZHZqNkxQZkpyYThsQkJiNUpyU2RkSGJUWmNZcUtGYXNwUXFQVjM0cTdXV3pTX1g3cHRUaXdIbUJsZ1pybmVHaXdyczl1M3NwZFBndEMwNXhGRWpNWDNhUEJINEZ4VzNKdklOUk9ESlgtazJQcTI1U3k2Y2NIcTh4a3BTRzFBTFBLNkk?oc=5","date":"2023-08-22","type":"regulatory","source":"BioPharma APAC","summary":"Everest Medicines' Partner Calliditas Therapeutics Gets FDA Priority Review for Nefecon® in IgA Nephropathy - BioPharma APAC","headline":"Everest Medicines' Partner Calliditas Therapeutics Gets FDA Priority Review for Nefecon® in IgA Nephropathy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPcl9mVm8yeWRCREpUT3dEd1NsMWlRRUdhczlWYjhwSnVCUjVHMU94VTVCb1d0cERVOU1Gb2tsWlF6QlJaZUZwdXI0SnZuSEVtb2FtQW5LUWZpNDJFVzlFQndfeVk2bVhkV2N5ekhwZTNuYmlmamtkUHMyZFdNZEpsNktzTXpNVjh6QUptZWVmSm9MN2ZJVDdFaUZPTjA2NURtVm96bVlMYw?oc=5","date":"2023-01-26","type":"pipeline","source":"Seeking Alpha","summary":"Travere Therapeutics: Upcoming 'PDUFA' Date For Kidney Disease Therapy Is Critical (TVTX) - Seeking Alpha","headline":"Travere Therapeutics: Upcoming 'PDUFA' Date For Kidney Disease Therapy Is Critical (TVTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNSWY3TXpWckZ1Vy1oa202NlUya1FyT0wwUGIzWmR3NjhlZkJsR2lNWW50NVpmdmxVN2llVVpKQmxwalJZV0xzXzZwWFdhR3lSUFhmdDJqUU12WXh0cDNHaGNlSWtPVGNiTU5BNHVWclpBZENvQVpPN01IbXpGSlQyblVyYm03VU5iYW9YUWhNdWpSYl9Fdmp4RHVn?oc=5","date":"2021-12-15","type":"regulatory","source":"PharmaLive","summary":"FDA grants Calliditas Therapeutics Accelerated Approval of Tarpeyo - PharmaLive","headline":"FDA grants Calliditas Therapeutics Accelerated Approval of Tarpeyo","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE9LaWIyVXNiZnNyQlVpV1dreGFnaXVBZ1hZeHMxVHVhTWZNdWw3d1hHcTc5enI1d0RxZ21Kd09wWkJGNzdOR0hKSllNZ1BRYWJlQWJlcTVETnZhUQ?oc=5","date":"2020-06-30","type":"pipeline","source":"MarketBeat","summary":"Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis $CALT - MarketBeat","headline":"Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis $CALT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOaUxCWmM4VUhBX2pFNFlfbTl4NWV3N1pLdDdOUUFLYnkzNzVWMVdmOUhGUktseFpQYjBlc1JMUEJrTXhqMG14enpJQ1JHS1Bya0YyTVdoT212cy15TjRQaDl6U2xYZVowaTBycVVIdmx2UjVXeEF4bzJKalVNckNocw?oc=5","date":"2020-04-29","type":"pipeline","source":"MarketBeat","summary":"Top Ovid Therapeutics (OVID) Competitors 2026 - MarketBeat","headline":"Top Ovid Therapeutics (OVID) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOMHhyRjNybGpiVWl4Qng4OGlYd2dLUDVnLUpDQTl3dzNsZWhrLVhmUDYyM1otREFQLWN4X1M2V2tQSGZ3dzVBMkUyTmkwbWRDQXhmcDd2WnhzNE1jZmNzNl9NcGg4NS1XSnN2RzdIbmRrUFpqX0ZRdmJvb3RreUZYdg?oc=5","date":"2020-04-29","type":"pipeline","source":"MarketBeat","summary":"Top Bicycle Therapeutics (BCYC) Competitors 2026 - MarketBeat","headline":"Top Bicycle Therapeutics (BCYC) Competitors 2026","sentiment":"neutral"}],"patents":[{"drugName":"Nefecon","drugSlug":"budesonide","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":1,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AstraZeneca","GlaxoSmithKline","Sanofi"],"therapeuticFocus":["Nephrology","Rare Diseases"],"financials":null,"yahoo":null}